Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$482.27 USD

482.27
956,306

-6.51 (-1.33%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.

McKesson (MCK) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

McKesson (MCK) Tops Q1 Earnings Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 10.06% and 4.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's Why McKesson (MCK) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Henry Schein (HSIC) Q2 Earnings Beat Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 0.82% and 4.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy, Sell or Hold McKesson (MCK) Before Q1 Earnings?

by Zacks Equity Research

McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.

Unlocking Q1 Potential of McKesson (MCK): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

McKesson (MCK) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

McKesson (MCK) reachead $629.09 at the closing of the latest trading day, reflecting a +1.96% change compared to its last close.

McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

McKesson (MCK) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

In the latest trading session, McKesson (MCK) closed at $600.16, marking a +0.74% move from the previous day.

Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) second-quarter results are likely to reflect strong performance in the Diagnostics segment.

Lower Volume Likely to Hurt GE HealthCare's (GEHC) Q2 Earnings

by Zacks Equity Research

GE HealthCare's (GEHC) second-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line results may reflect better pricing.

Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings

by Zacks Equity Research

Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.

McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

McKesson (MCK) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

McKesson (MCK) closed at $585.74 in the latest trading session, marking a +0.47% move from the prior day.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.

Intuitive Surgical (ISRG) Hits All-Time High: Will It Go Higher?

by Zacks Equity Research

Intuitive Surgical (ISRG) reported robust quarterly performance last week, and its shares touched an all-time high. Will the company's fundamentals support further upside?

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

McKesson (MCK) Stock Moves -0.32%: What You Should Know

by Zacks Equity Research

In the latest trading session, McKesson (MCK) closed at $582.06, marking a -0.32% move from the previous day.

McKesson (MCK) Gains 26% Year to Date: What's Backing the Rally?

by Zacks Equity Research

McKesson's (MCK) shares have risen 1.5% year to date on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.

Sheraz Mian headshot

Q2 Earnings Season Scorecard and Analyst Reports for Microsoft, Eli Lilly & UnitedHealth

by Sheraz Mian

Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Microsoft (MSFT), Eli Lilly (LLY) and UnitedHealth (UNH), as well as a micro-cap stock Tile Shop Holdings (TTSH).

Here's Why McKesson (MCK) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.